Risk factors, biochemical markers, and genetic polymorphisms in early coronary artery disease

Izar, Maria Cristina de Oliveira; Fonseca, Francisco Antônio Helfenstein; Ihara, Sílvia Saiuli Miki; Kasinski, Nelson; Sang, Won Han; Lopes, I.; Pinto, Leonor do Espírito Santo de Almeida; Relvas, W.G.M.; Lourenço, Dayse Maria; Tufik, Sérgio; Paola, Ângelo Amato Vincenzo de; Carvalho, Antônio Carlos

doi:10.1590/s0066-782x2003000400003

Cited by 17 publications

(15 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The data here are compatible to previously published reports as patients who develop with coronary artery disease when young are characterized by the presence of the aforementioned risk factors amongst others including obesity, systemic arterial hypertension, diabetes mellitus, unfavorable lipid profile, high levels of apolipoprotein B and low levels of apolipoprotein AI [8]. It is also important to stress that currently the majority of patients submitted to coronary artery bypass surgery are old, male, smokers and in bad physical conditions [9].…”

Section: Discussionsupporting

confidence: 91%

<![CDATA[<B>Evaluation of platelet aggregation and level of fibrinogen in patients with cardiovascular diseases and the correlation of taking aspirin with coronary risk factors</B>]]>

Gabriel¹,

Trist�o²,

Izar³

et al. 2006

Braz. j. cardiovasc. surg.

View full text Add to dashboard Cite

Avaliação da agregação plaquetária e dosagem do fibrinogênio em pacientes com doenças cardiovasculares e sua correlação com o uso de aspirina e fatores de risco coronariano Evaluation of platelet aggregation and level of fibrinogen in patients with cardiovascular diseases and the correlation of taking aspirin with coronary risk factors Abstract Objective: To evaluate aspirin resistance in patients with cardiovascular diseases and to compare the amount of serum fibrinogen in patients taking aspirin with those who do not. To correlate the platelet aggregation and serum fibrinogen to cardiovascular risk parameters.Method: Eighty-two patients were divided into two groups: Group 1 -41 patients who took 100mg aspirin daily and Group 2 -41 patients who did not utilize platelet antiaggregates. Epidemiological data were collected including age, gender and information on smoking and alcohol intake and serum fibrinogen and platelet aggregation were measured.Results: In the groups analyzed, advanced age (p=0.011), smoking (p=0.009) and alcoholism (p=0.007) were directly associated to the serum fibrinogen level. There were no correlations between smoking, alcoholism, serum fibrinogen and platelet aggregation values (p>0.05). In Group 1, 29% of the patients presented with aspirin resistance. Of these, smokers (p=0.029) and alcoholics (p=0.033) had higher serum fibrinogen levels. Conclusion: Aspirin resistance was present in a high number of patients. Moreover, advanced age, smoking and alcoholism had a direct influence on the serum fibrinogen levels.

show abstract

Section: Discussionsupporting

confidence: 91%

<![CDATA[<B>Evaluation of platelet aggregation and level of fibrinogen in patients with cardiovascular diseases and the correlation of taking aspirin with coronary risk factors</B>]]>

Gabriel¹,

Trist�o²,

Izar³

et al. 2006

Braz. j. cardiovasc. surg.

View full text Add to dashboard Cite

show abstract

“…In cardiovascular diseases, blood concentrations of lipoproteins and lipids are influenced by hereditable risk factors and by environmental factors (Kannel et al 1961;Miller and Miller 1975). Several studies suggested that increased triglyceride levels and unfavourable lipid profile are independent risk factors for cardio-and cerebrovascular diseases (Meigs et al 2002;Izar et al 2003;Zhao et al 2010). In 2001, the National Cholesterol Education Program (NCEP) summarized other markers of coronary risk, classified as risk factors related to lifestyle (physical inactivity; obesity; and atherogenic diet) and emerging risk factors (lipoproteins; homocysteine; altered fasting glycaemia; and evidence of subclinical atherosclerosis) (2001).…”

Section: Introductionmentioning

confidence: 99%

“…The role of APOA5 alleles had already been widely studied (Szalai et al 2004;Vaessen et al 2006;Martinelli et al 2007;Maasz and Kisfali 2008a, b;Feitosa et al 2011), and a growing number of triglyceride modifying alleles are being identified (Ordovas et al 1991;Dallinga-Thie et al 1997; Baroni et al 2003;Talmud et al 2009). Some of them are associated with increased, while others with decreased triglyceride levels Baroni et al 2003;Izar et al 2003;Kathiresan and Melander 2008b;Kathiresan et al 2009); the analysis of their functional role in different diseases had already begun (Pedro-Botet et al 1992; Baroni et al 2003;Izar et al 2003;Frikke-Schmidt et al 2004;Ma et al 2004;Souverein et al 2005;Havasi et al 2006;Vaessen et al 2006;Freiberg et al 2008;Willer et al 2008;Kathiresan and Melander 2008a;Kathiresan et al 2009;Labreuche et al 2009;Perez-Martinez et al 2011). As increased levels of certain triglycerides can associate with the development of different vascular diseases, positive association between triglyceride level-elevating SNPs and polygenic vascular diseases has already been reported (Kannel et al 1961;Miller and Miller 1975;Salonen et al 1982;Ordovas et al 1991;Pedro-Botet et al 1992;Meigs et al 2002;Baroni et al 2003;Izar et al 2003;…”

Section: Introductionmentioning

confidence: 99%

“…Some of them are associated with increased, while others with decreased triglyceride levels Baroni et al 2003;Izar et al 2003;Kathiresan and Melander 2008b;Kathiresan et al 2009); the analysis of their functional role in different diseases had already begun (Pedro-Botet et al 1992; Baroni et al 2003;Izar et al 2003;Frikke-Schmidt et al 2004;Ma et al 2004;Souverein et al 2005;Havasi et al 2006;Vaessen et al 2006;Freiberg et al 2008;Willer et al 2008;Kathiresan and Melander 2008a;Kathiresan et al 2009;Labreuche et al 2009;Perez-Martinez et al 2011). As increased levels of certain triglycerides can associate with the development of different vascular diseases, positive association between triglyceride level-elevating SNPs and polygenic vascular diseases has already been reported (Kannel et al 1961;Miller and Miller 1975;Salonen et al 1982;Ordovas et al 1991;Pedro-Botet et al 1992;Meigs et al 2002;Baroni et al 2003;Izar et al 2003;Pennacchio and Rubin 2003;Ma et al 2004;Szalai et al 2004;Souverein et al 2005;Havasi et al 2006;Vaessen et al 2006;Nordestgaard et al 2007;Saidi et al 2007;Willer et al 2008;Freiberg et al 2008;Maasz and Kisfali 2008a, b;…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Triglyceride Level-Influencing Functional Variants of the ANGPTL3, CILP2, and TRIB1 Loci in Ischemic Stroke

et al. 2011

View full text Add to dashboard Cite

Stroke is a common multifactorial disease, and the third leading cause of death worldwide, which results in serious long-term mental and physical disability among survivors. The role of affected triglyceride metabolism in the development of ischemic stroke is under extensive investigations. Here, we examined three SNPs, rs12130333 located within the ANGPTL3 locus; rs16996148 residing at the CILP2 gene locus; and rs17321515 at the TRIB1 locus, which were originally reported in association with decreased triglyceride levels; therefore, we investigated their possible protective effect against the development of ischemic stroke. A total of 459 Caucasian stroke patients, stratified as large-vessel, small-vessel, and mixed stroke groups, and 168 control subjects were genotyped using PCR-RFLP methods. As a result, we could not detect any differences in triglyceride or total cholesterol levels in relation to any allelic variants of rs16996148, rs17321515, or rs12130333 SNPs. No correlation was found between the minor alleles rs16996148-T (P = 0.881), rs17321515-G (P = 0.070), or rs12130333-T allele (P = 0.757) and the risk for development of stroke. The data presented here suggest different scale of effect of triglyceride modifier alleles and also their variable susceptibility or protective nature.

show abstract

“…Recently, other triglyceride modifying polymorphisms came into focus, which may also have role in development of different diseases [2,12,15,16,19,[23][24][25]. Some variants of these are mentioned in connection with increased, while others with decreased triglyceride levels [16,23,24,26,27]. The elevated levels of certain triglycerides may have a higher risk for several vascular diseases, moreover significant associations between triglyceride level-elevating and polymorphisms were confirmed [1, 2, 4, 5, 12-15, 17, 28, 26, 29-32, 25].…”

mentioning

confidence: 99%

Functional Variants of Lipid Level Modifier MLXIPL, GCKR, GALNT2, CILP2, ANGPTL3 and TRIB1 Genes in Healthy Roma and Hungarian Populations

Sümegi

Magyari

Kövesdi

et al. 2015

Pathol. Oncol. Res.

View full text Add to dashboard Cite

The role of triglyceride metabolism in different diseases, such as cardiovascular or cerebrovascular diseases is still under extensive investigations. In genome-wide studies several polymorphisms have been reported, which are highly associated with plasma lipid level changes. Our goal was to examine eight variants: rs12130333 at the ANGPTL3, rs16996148 at the CILP2, rs17321515 at the TRIB1, rs17145738 and rs3812316 of the MLXIPL, rs4846914 at GALNT2, rs1260326 and rs780094 residing at the GCKR loci. A total of 399 Roma (Gypsy) and 404 Hungarian population samples were genotyped using PCR-RFLP method. Significant differences were found between Roma and Hungarian population samples in both MLXIPL variants (C allele frequency of rs17145738: 94.1% vs. 85.6%, C allele frequency of rs3812316: 94.2% vs. 86.8% in Romas vs. in Hungarians, p < 0.05), in ANGPTL3 (T allele frequency of rs1213033: 12.2% vs. 18.5% in Romas vs. Hungarians, p < 0.05) and GALNT2 (G allele frequency of rs4846914: 46.6% vs. 54.5% Romas vs. in Hungarians, p < 0.05), while no differences over SNPs could be verified and the known minor alleles showed no correlation with triglyceride levels in any population samples. The current study revealed fundamental differences of known triglyceride modifying SNPs in Roma population. Failure of finding evidence for affected triglyceride metabolism shows that these susceptibility genes are much less effective compared for example to the apolipoprotein A5 gene.

show abstract

Risk factors, biochemical markers, and genetic polymorphisms in early coronary artery disease

Cited by 17 publications

References 39 publications

<![CDATA[<B>Evaluation of platelet aggregation and level of fibrinogen in patients with cardiovascular diseases and the correlation of taking aspirin with coronary risk factors</B>]]>

<![CDATA[<B>Evaluation of platelet aggregation and level of fibrinogen in patients with cardiovascular diseases and the correlation of taking aspirin with coronary risk factors</B>]]>

Triglyceride Level-Influencing Functional Variants of the ANGPTL3, CILP2, and TRIB1 Loci in Ischemic Stroke

Functional Variants of Lipid Level Modifier MLXIPL, GCKR, GALNT2, CILP2, ANGPTL3 and TRIB1 Genes in Healthy Roma and Hungarian Populations

Contact Info

Product

Resources

About